
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3215863/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review. Gastroenterology, 2012, 142, 46-54.e42.	0.6	4,013
2	Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet, The, 2017, 390, 2769-2778.	6.3	3,705
3	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine, 2016, 375, 1946-1960.	13.9	1,316
4	Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease. New England Journal of Medicine, 2012, 367, 1519-1528.	13.9	984
5	Natalizumab for Active Crohn's Disease. New England Journal of Medicine, 2003, 348, 24-32.	13.9	834
6	Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2020, 5, 667-678.	3.7	804
7	Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis. Gastroenterology, 2014, 146, 392-400.e3.	0.6	778
8	Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis. New England Journal of Medicine, 2012, 367, 616-624.	13.9	716
9	Individual intestinal symbionts induce a distinct population of RORÎ ³ ⁺ regulatory T cells. Science, 2015, 349, 993-997.	6.0	707
10	Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies. Gastroenterology, 2013, 145, 996-1006.	0.6	670
11	European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis, 2008, 2, 24-62.	0.6	473
12	Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut, 2008, 57, 923-929.	6.1	426
13	NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflammatory Bowel Diseases, 2011, 17, 1359-1372.	0.9	366
14	The Global Incidence of Appendicitis. Annals of Surgery, 2017, 266, 237-241.	2.1	362
15	Heteroatomâ€Doped and Oxygenâ€Functionalized Nanocarbons for Highâ€Performance Supercapacitors. Advanced Energy Materials, 2020, 10, 2001239.	10.2	362
16	Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. New England Journal of Medicine, 2016, 374, 1754-1762.	13.9	361
17	Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet, The, 2005, 365, 1794-1796.	6.3	305
18	Implications of COVID-19 for patients with pre-existing digestive diseases. The Lancet Gastroenterology and Hepatology, 2020, 5, 425-427.	3.7	274

#	Article	IF	CITATIONS
19	A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, inÂPatients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 1485-1493.e2.	2.4	256
20	Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. Journal of Crohn's and Colitis, 2007, 1, 10-20.	0.6	255
21	Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology, 1994, 107, 1031-1039.	0.6	254
22	Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 2021, 385, 1280-1291.	13.9	243
23	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2020, 69, 984-990.	6.1	232
24	Inflammatory Bowel Disease: A Canadian Burden of Illness Review. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 811-817.	1.8	229
25	Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis. Gastroenterology, 2015, 148, 344-354.e5.	0.6	226
26	Th17 plasticity and its relevance to inflammatory bowel disease. Journal of Autoimmunity, 2018, 87, 38-49.	3.0	214
27	Fatty acids, eicosanoids and PPAR gamma. European Journal of Pharmacology, 2016, 785, 44-49.	1.7	213
28	The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association. American Journal of Gastroenterology, 2010, 105, 2412-2419.	0.2	197
29	Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology, 2020, 158, 2123-2138.e8.	0.6	189
30	Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology, 2020, 159, 6-13.e6.	0.6	185
31	Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut, 2010, 59, 767-774.	6.1	184
32	Cumulative Incidence of Second Intestinal Resection in Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Studies. American Journal of Gastroenterology, 2014, 109, 1739-1748.	0.2	178
33	Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology, 2018, 154, 1660-1671.	0.6	175
34	Decreasing Colectomy Rates for Ulcerative Colitis: A Population-Based Time Trend Study. American Journal of Gastroenterology, 2012, 107, 1879-1887.	0.2	174
35	Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology, 2020, 158, 2139-2149.e14.	0.6	171
36	Increased Prevalence of Circulating Novel IL-17 Secreting Foxp3 Expressing CD4+ T Cells and Defective Suppressive Function of Circulating Foxp3+ Regulatory Cells Support Plasticity Between Th17 and Regulatory T Cells in Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2013, 19, 2522-2534.	0.9	162

#	Article	IF	CITATIONS
37	Postoperative Complications and Mortality Following Colectomy for Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2011, 9, 972-980.	2.4	154
38	IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. Journal of Crohn's and Colitis, 2020, 14, 23-32.	0.6	149
39	TRPM8 activation attenuates inflammatory responses in mouse models of colitis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7476-7481.	3.3	147
40	Clinical, endoscopic and radiographic outcomes with ustekinumab in medicallyâ€refractory Crohn's disease: real world experience from a multicentre cohort. Alimentary Pharmacology and Therapeutics, 2017, 45, 1232-1243.	1.9	141
41	Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3. American Journal of Gastroenterology, 2014, 109, 1771-1780.	0.2	140
42	Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. American Journal of Gastroenterology, 2017, 112, 1840-1848.	0.2	140
43	The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management. Nutrients, 2019, 11, 1019.	1.7	140
44	The challenge of indication extrapolation for infliximab biosimilars. Biologicals, 2014, 42, 177-183.	0.5	138
45	Bowel Ultrasonography in the Management of Crohn's Disease. A Review with Recommendations of an International Panel of Experts. Inflammatory Bowel Diseases, 2016, 22, 1168-1183.	0.9	137
46	A comparative study on defect estimation using XPS and Raman spectroscopy in few layer nanographitic structures. Physical Chemistry Chemical Physics, 2016, 18, 22160-22167.	1.3	136
47	Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised doubleâ€blind placeboâ€controlled study. United European Gastroenterology Journal, 2015, 3, 294-302.	1.6	135
48	Successful infliximab treatment for steroid-refractory celiac disease: A case report. Gastroenterology, 2002, 122, 800-805.	0.6	132
49	Polyunsaturated fatty acids and inflammation. IUBMB Life, 2015, 67, 659-667.	1.5	129
50	Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review. Clinical Gastroenterology and Hepatology, 2020, 18, 304-312.	2.4	129
51	Longâ€ŧerm efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Alimentary Pharmacology and Therapeutics, 2018, 48, 65-77.	1.9	128
52	Atomic water channel controlling remarkable properties of a single brain microtubule: Correlating single protein to its supramolecular assembly. Biosensors and Bioelectronics, 2013, 47, 141-148.	5.3	124
53	Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Alimentary Pharmacology and Therapeutics, 2004, 20, 1337-1346.	1.9	121
54	Environment and the Inflammatory Bowel Diseases. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, e18-e24.	1.8	121

#	Article	IF	CITATIONS
55	[2+2] Photochemical Cycloaddition in Organic Synthesis. European Journal of Organic Chemistry, 2020, 1310-1326.	1.2	119
56	Modern management of perianal fistulas in Crohn's disease: future directions. Gut, 2018, 67, 1181-1194.	6.1	114
57	Smooth Muscle Hyperplasia/Hypertrophy is the Most Prominent Histological Change in Crohn's Fibrostenosing Bowel Strictures: A Semiquantitative Analysis by Using a Novel Histological Grading Scheme. Journal of Crohn's and Colitis, 2017, 11, 92-104.	0.6	113
58	A review on metal nitrides/oxynitrides as an emerging supercapacitor electrode beyond oxide. Korean Journal of Chemical Engineering, 2018, 35, 1389-1408.	1.2	113
59	Evolution and defect analysis of vertical graphene nanosheets. Journal of Raman Spectroscopy, 2014, 45, 642-649.	1.2	109
60	Comparison of cytokine modulation by natural peroxisome proliferator–activated receptor γ ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells—potential for dietary modulation of peroxisome proliferator–activated receptor γ in intestinal inflammation. American Journal of Clinical Nutrition, 2008, 87, 939-948.	2.2	107
61	A Randomized Trial Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy. American Journal of Gastroenterology, 2018, 113, 225-234.	0.2	106
62	Review article: managing the adverse events caused by antiâ€TNF therapy in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 664-680.	1.9	104
63	Review: Anti-adhesion molecule therapy for inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2010, 3, 239-258.	1.4	97
64	Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies. Gastroenterology, 2015, 149, 928-937.	0.6	97
65	Review article: chronic viral infection in the antiâ€ŧumour necrosis factor therapy era in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2010, 31, 20-34.	1.9	96
66	Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2013, 38, 447-459.	1.9	96
67	Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease. Inflammatory Bowel Diseases, 2017, 23, 833-839.	0.9	94
68	Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 578-590.e4.	2.4	94
69	Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Safety, 2019, 42, 751-768.	1.4	93
70	Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in <i>db/db</i> mice. American Journal of Physiology - Renal Physiology, 2009, 296, F700-F708.	1.3	91
71	Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders. Clinical Gastroenterology and Hepatology, 2018, 16, 1374-1384.	2.4	91
72	Polyunsaturated Fatty Acids in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2013, 19, 650-661.	0.9	89

#	Article	IF	CITATIONS
73	Mesalazine in Inflammatory Bowel Disease: A Trendy Topic Once Again?. Canadian Journal of Gastroenterology & Hepatology, 2010, 24, 127-133.	1.8	88
74	Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. European Journal of Gastroenterology and Hepatology, 2001, 13, 191-192.	0.8	86
75	Dietary modulation of peroxisome proliferator-activated receptor gamma. Gut, 2009, 58, 586-593.	6.1	85
76	Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2008, 28, 674-688.	1.9	84
77	Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflammatory Bowel Diseases, 2011, 17, 1792-1799.	0.9	84
78	Probiotics in inflammatory bowel disease: is it all gut flora modulation?. Gut, 2004, 53, 620-622.	6.1	83
79	A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways. Journal of Crohn's and Colitis, 2020, 14, 935-947.	0.6	81
80	Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy. Inflammatory Bowel Diseases, 2016, 22, 638-647.	0.9	80
81	Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. The Lancet Gastroenterology and Hepatology, 2020, 5, 598-606.	3.7	79
82	The Increasing Weight of Crohn's Disease Subjects in Clinical Trials. Inflammatory Bowel Diseases, 2013, 19, 2949-2956.	0.9	78
83	Prevention of biliary stent occlusion using cyclical antibiotics and ursodeoxycholic acid Gut, 1994, 35, 1757-1759.	6.1	76
84	From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. Clinical and Experimental Immunology, 2016, 184, 137-146.	1.1	76
85	Urinary-type Plasminogen Activator (uPA) Expression and uPA Receptor Localization Are Regulated by α3β1Integrin in Oral Keratinocytes. Journal of Biological Chemistry, 2000, 275, 23869-23876.	1.6	73
86	Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease. Inflammatory Bowel Diseases, 2016, 22, 1779-1792.	0.9	73
87	Bioactive natural compounds for the treatment of gastrointestinal disorders. Clinical Science, 2003, 104, 547-556.	1.8	72
88	Development of the IBD Disk. Inflammatory Bowel Diseases, 2017, 23, 333-340.	0.9	72
89	Modulation of dendritic cell phenotype and functionin anin vitromodel of the intestinal epithelium. European Journal of Immunology, 2006, 36, 864-874.	1.6	71
90	Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations: Table 1 Journal of Crohn's and Colitis, 2015, 9, 685-691.	0.6	71

#	Article	IF	CITATIONS
91	The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1329-1338.	1.9	71
92	Clinic-based Point of Care Transabdominal Ultrasound for Monitoring Crohn's Disease: Impact on Clinical Decision Making. Journal of Crohn's and Colitis, 2015, 9, 795-801.	0.6	69
93	Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancer. Therapeutic Advances in Gastroenterology, 2011, 4, 49-62.	1.4	68
94	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology, 2021, 160, 1452-1460.e21.	0.6	68
95	Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Alimentary Pharmacology and Therapeutics, 2002, 16, 389-398.	1.9	67
96	Upper-gastrointestinal bleeding secondary to peptic ulcer disease: Incidence and outcomes. World Journal of Gastroenterology, 2014, 20, 17568.	1.4	67
97	Influence of substrate on nucleation and growth of vertical graphene nanosheets. Applied Surface Science, 2015, 349, 576-581.	3.1	67
98	Supercapacitive vertical graphene nanosheets in aqueous electrolytes. Nano Structures Nano Objects, 2017, 10, 42-50.	1.9	67
99	Risk of Comorbidities on Postoperative Outcomes in Patients With Inflammatory Bowel Disease. Archives of Surgery, 2011, 146, 959.	2.3	66
100	Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflammatory Bowel Diseases, 2021, 27, 994-1007.	0.9	66
101	Targeted Biopsies Identify Larger Proportions of Patients With Colonic Neoplasia Undergoing High-Definition Colonoscopy, Dye Chromoendoscopy, or Electronic Virtual Chromoendoscopy. Clinical Gastroenterology and Hepatology, 2016, 14, 704-712.e4.	2.4	65
102	The spectrum of ischaemic colitis. European Journal of Gastroenterology and Hepatology, 1999, 11, 295-304.	0.8	63
103	Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report. Inflammatory Bowel Diseases, 2012, 18, 152-160.	0.9	63
104	Review article: dermatological complications of immunosuppressive and anti-TNF therapy in in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2013, 38, 1002-1024.	1.9	63
105	Plasma-tuneable oxygen functionalization of vertical graphenes enhance electrochemical capacitor performance. Energy Storage Materials, 2018, 14, 297-305.	9.5	63
106	Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ulcerativeÂcolitis. Gastrointestinal Endoscopy, 2017, 86, 1118-1127.e5.	0.5	62
107	Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481988419.	1.4	62
108	Infliximab use in Crohn??s disease: impact on health care resources in the UK. European Journal of Gastroenterology and Hepatology, 2005, 17, 1047-1052.	0.8	61

#	Article	IF	CITATIONS
109	Cross-Sectional Analysis of Overall Dietary Intake and Mediterranean Dietary Pattern in Patients with Crohn's Disease. Nutrients, 2018, 10, 1761.	1.7	61
110	Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. Journal of Crohn's and Colitis, 2016, 10, 418-428.	0.6	60
111	Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19. Gastroenterology, 2020, 159, 1170-1172.e1.	0.6	59
112	Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. Journal of Crohn's and Colitis, 2021, 15, 1120-1129.	0.6	59
113	Long-Term Results of Subtotal Colectomy and Evidence of Noncolonic Involvement in Patients with Idiopathic Slow-Transit Constipation. Scandinavian Journal of Gastroenterology, 1996, 31, 1083-1091.	0.6	57
114	Surgical closure of atrial septal defects in adults: effect of age at operation on outcome. British Heart Journal, 2002, 88, 485-487.	2.2	57
115	Development and Validation of a Novel Computed-Tomography Enterography Radiomic Approach for Characterization of Intestinal Fibrosis in Crohn's Disease. Gastroenterology, 2021, 160, 2303-2316.e11.	0.6	57
116	Non-Specific Abdominal Pain and Air Pollution: A Novel Association. PLoS ONE, 2012, 7, e47669.	1.1	57
117	Postoperative complications following colectomy for ulcerative colitis: A validation study. BMC Gastroenterology, 2012, 12, 39.	0.8	56
118	Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment. Clinical Gastroenterology and Hepatology, 2014, 12, 434-442.e1.	2.4	56
119	Living with Inflammatory Bowel Disease: A Crohn's and Colitis Canada Survey. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 77-84.	0.8	56
120	IBD: In Food We Trust. Journal of Crohn's and Colitis, 2016, 10, 1351-1361.	0.6	56
121	Ulcerative Colitis Patients With Clostridium difficile are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study. American Journal of Gastroenterology, 2016, 111, 691-704.	0.2	56
122	Dietary n-3 PUFA May Attenuate Experimental Colitis. Mediators of Inflammation, 2018, 2018, 1-10.	1.4	56
123	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 857-873.	8.2	56
124	Coral-Like Yolk–Shell-Structured Nickel Oxide/Carbon Composite Microspheres for High-Performance Li-Ion Storage Anodes. Nano-Micro Letters, 2019, 11, 3.	14.4	54
125	Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings. Endoscopy, 2015, 47, 726-734.	1.0	53
126	Endoscopic and histologic features of sodium phosphate bowel preparation-induced colonic ulceration: Case report and review. Gastrointestinal Endoscopy, 2002, 55, 584-587.	0.5	52

#	Article	IF	CITATIONS
127	Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease. Inflammatory Bowel Diseases, 2017, 23, 461-472.	0.9	52
128	Process-specific mechanisms of vertically oriented graphene growth in plasmas. Beilstein Journal of Nanotechnology, 2017, 8, 1658-1670.	1.5	52
129	Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade [®]] or Conventional Therapy. Journal of Crohn's and Colitis, 2017, 11, jjw221.	0.6	51
130	Further observations of stage-specific effects seen after short-term hypophysectomy in the rat. Tissue and Cell, 1991, 23, 613-630.	1.0	49
131	Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093462.	1.4	48
132	Systematic review: the shortâ€ŧerm and longâ€ŧerm efficacy of adalimumab following discontinuation of infliximab. Alimentary Pharmacology and Therapeutics, 2009, 30, 977-986.	1.9	47
133	Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2011, 4, 129-143.	1.4	47
134	Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease?. Gut, 2006, 55, 6-8.	6.1	46
135	Inflammatory Bowel Diseases and Food Additives: To Add Fuel on the Flames!. Nutrients, 2019, 11, 1111.	1.7	46
136	Mesoporous carbon nanofiber engineered for improved supercapacitor performance. Korean Journal of Chemical Engineering, 2019, 36, 312-320.	1.2	46
137	Diverse patterns of expression of the 67-kD laminin receptor in human small intestinal mucosa: potential binding sites for prion proteins?. Journal of Pathology, 2000, 191, 318-322.	2.1	45
138	Degree of Creeping Fat Assessed by Computed Tomography Enterography is Associated with Intestinal Fibrotic Stricture in Patients with Crohn's Disease: A Potentially Novel Mesenteric Creeping Fat Index. Journal of Crohn's and Colitis, 2021, 15, 1161-1173.	0.6	45
139	PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system. Gut, 2022, 71, 889-898.	6.1	45
140	Cellular prion protein is expressed in the human enteric nervous system. Nature Medicine, 2000, 6, 840-841.	15.2	44
141	Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. The Lancet Gastroenterology and Hepatology, 2019, 4, 287-295.	3.7	44
142	Inflammatory Bowel Disease Cause-specific Mortality. Inflammatory Bowel Diseases, 2014, 20, 2483-2492.	0.9	43
143	Prevalence and Anatomic Distribution of Serrated and Adenomatous Lesions in Patients with Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-8.	0.8	43
144	A multimodal (FACILE) classification for optical diagnosis of inflammatory bowel disease associated neoplasia. Endoscopy, 2019, 51, 133-141.	1.0	43

#	Article	IF	CITATIONS
145	A Diversified Dietary Pattern Is Associated With a Balanced Gut Microbial Composition of Faecalibacterium and Escherichia/Shigella in Patients With Crohn's Disease in Remission. Journal of Crohn's and Colitis, 2020, 14, 1547-1557.	0.6	43
146	Proteolytic modification of laminins: Functional consequences. Microscopy Research and Technique, 2000, 51, 238-246.	1.2	42
147	O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNα. Inflammatory Bowel Diseases, 2016, 22, S1.	0.9	42
148	Enhanced supercapacitance of activated vertical graphene nanosheets in hybrid electrolyte. Journal of Applied Physics, 2017, 122, .	1.1	42
149	Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era. Gut, 2019, 68, 562-572.	6.1	42
150	MXene-based 3D porous macrostructures for electrochemical energy storage. JPhys Materials, 2020, 3, 022001.	1.8	42
151	Ambient Ozone Concentrations and the Risk of Perforated and Nonperforated Appendicitis: A Multicity Case-Crossover Study. Environmental Health Perspectives, 2013, 121, 939-943.	2.8	41
152	Intrapartum Corticosteroid use Significantly Increases the Risk of Gestational Diabetes in Women with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2015, 9, 223-230.	0.6	41
153	Fractal, Scale Free Electromagnetic Resonance of a Single Brain Extracted Microtubule Nanowire, a Single Tubulin Protein and a Single Neuron. Fractal and Fractional, 2020, 4, 11.	1.6	41
154	An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis. Gastroenterology, 2021, 160, 1558-1569.e8.	0.6	41
155	Review article: novel oralâ€ŧargeted therapies in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 1610-1622.	1.9	40
156	Synergism between Tat and VP16 in Trans-activation of HIV-1 LTR. Journal of Molecular Biology, 1993, 234, 610-619.	2.0	39
157	Ustekinumab for the treatment of Crohn's disease: can it find its niche?. Therapeutic Advances in Gastroenterology, 2016, 9, 26-36.	1.4	39
158	Beyond white light: optical enhancement in conjunction with magnification colonoscopy for the assessment of mucosal healing in ulcerative colitis. Endoscopy, 2017, 49, 553-559.	1.0	39
159	Scalable transfer of vertical graphene nanosheets for flexible supercapacitor applications. Nanotechnology, 2017, 28, 415702.	1.3	39
160	Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease: An International Multicenter Study. Inflammatory Bowel Diseases, 2018, 24, 2001-2006.	0.9	39
161	Multi-channel-contained few-layered MoSe2 nanosheet/N-doped carbon hybrid nanofibers prepared using diethylenetriamine as anodes for high-performance sodium-ion batteries. Journal of Industrial and Engineering Chemistry, 2019, 75, 100-107.	2.9	39
162	Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn's Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 2030-2037.	2.4	39

#	Article	IF	CITATIONS
163	Dietary microparticles implicated in Crohn's disease can impair macrophage phagocytic activity and act as adjuvants in the presence of bacterial stimuli. Inflammation Research, 2007, 56, 353-361.	1.6	38
164	Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus. Journal of Crohn's and Colitis, 2012, 6, 248-258.	0.6	38
165	Phase-pure VO2 nanoporous structure for binder-free supercapacitor performances. Scientific Reports, 2019, 9, 4621.	1.6	38
166	Absence of detectable measles virus genome sequence in inflammatory bowel disease tissues and peripheral blood lymphocytes. Journal of Medical Virology, 1998, 55, 243-249.	2.5	37
167	Inventing atomic resolution scanning dielectric microscopy to see a single protein complex operation live at resonance in a neuron without touching or adulterating the cell. Journal of Integrative Neuroscience, 2016, 15, 435-462.	0.8	37
168	Designing metal oxide-vertical graphene nanosheets structures for 2.6 V aqueous asymmetric electrochemical capacitor. Journal of Industrial and Engineering Chemistry, 2019, 72, 107-116.	2.9	37
169	Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. World Journal of Gastroenterology, 2015, 21, 1251.	1.4	37
170	Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 479-484.	0.9	36
171	Design and Construction of a Brain-Like Computer: A New Class of Frequency-Fractal Computing Using Wireless Communication in a Supramolecular Organic, Inorganic System. Information (Switzerland), 2014, 5, 28-100.	1.7	36
172	A Self-Operating Time Crystal Model of the Human Brain: Can We Replace Entire Brain Hardware with a 3D Fractal Architecture of Clocks Alone?. Information (Switzerland), 2020, 11, 238.	1.7	36
173	Constitutive androstane receptor regulates the intestinal mucosal response to injury. British Journal of Pharmacology, 2017, 174, 1857-1871.	2.7	35
174	Aging effects on vertical graphene nanosheets and their thermal stability. Indian Journal of Physics, 2018, 92, 337-342.	0.9	35
175	Longâ€ŧerm safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2018, 47, 219-228.	1.9	35
176	Influences of Intestinal Bacteria in Human Inflammatory Bowel Disease. Infectious Disease Clinics of North America, 2010, 24, 977-993.	1.9	34
177	Thermal Conductivity and Pressure-Dependent Raman Studies of Vertical Graphene Nanosheets. Journal of Physical Chemistry C, 2016, 120, 25092-25100.	1.5	34
178	Temporal-stability of plasma functionalized vertical graphene electrodes for charge storage. Journal of Power Sources, 2018, 401, 37-48.	4.0	34
179	Incidence of Appendicitis over Time: A Comparative Analysis of an Administrative Healthcare Database and a Pathology-Proven Appendicitis Registry. PLoS ONE, 2016, 11, e0165161.	1.1	34
180	Blockade of IL-23: What is in the Pipeline?. Journal of Crohn's and Colitis, 2022, 16, ii64-ii72.	0.6	34

#	Article	IF	CITATIONS
181	Opposing Effects of Smoking in Ulcerative Colitis and Crohn's Disease May Be Explained by Differential Effects on Dendritic Cells. Inflammatory Bowel Diseases, 2014, 20, 800-810.	0.9	33
182	Small molecule oral targeted therapies in ulcerative colitis. The Lancet Gastroenterology and Hepatology, 2020, 5, 850-861.	3.7	33
183	Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss Alimentary Pharmacology and Therapeutics, 1996, 10, 321-326.	1.9	32
184	Anti-endomysial antibody negative celiac disease: does additional serological testing help?. Digestive Diseases and Sciences, 2001, 46, 214-221.	1.1	32
185	Management of gastrointestinal haemorrhage. Postgraduate Medical Journal, 2002, 78, 4-14.	0.9	32
186	Perturbation of the Human Microbiome as a Contributor to Inflammatory Bowel Disease. Pathogens, 2014, 3, 510-527.	1.2	32
187	Development and validation of the SIMPLE endoscopic classification of diminutive and small colorectal polyps. Endoscopy, 2018, 50, 779-789.	1.0	32
188	Interaction of cholecystokinin and somatostatin with a selective μ-opioid agonist and μ- and κ- antagonists in thermoregulation. Brain Research, 1997, 745, 152-157.	1.1	31
189	Detection of persistent measles virus infection in Crohn's disease: current status of experimental work. Gut, 2001, 48, 748-752.	6.1	31
190	Gene expression profiling and putative biomarkers of calves 3 months after infection with Mycobacterium avium subspecies paratuberculosis. Veterinary Immunology and Immunopathology, 2014, 160, 107-117.	0.5	31
191	Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. Journal of Crohn's and Colitis, 2017, 11, 811-819.	0.6	31
192	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterology Journal, 2021, 9, 451-460.	1.6	31
193	Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. The Lancet Gastroenterology and Hepatology, 2022, 7, 666-678.	3.7	31
194	Inventing a co-axial atomic resolution patch clamp to study a single resonating protein complex and ultra-low power communication deep inside a living neuron cell. Journal of Integrative Neuroscience, 2016, 15, 403-433.	0.8	30
195	Predicting inpatient hypoglycaemia in hospitalized patients with diabetes: a retrospective analysis of 9584 admissions with diabetes. Diabetic Medicine, 2017, 34, 1385-1391.	1.2	30
196	Interfering with interferons in inflammatory bowel disease. Gut, 2005, 55, 1071-1073.	6.1	29
197	Histological and molecular diversity and heterogeneity of precancerous lesions associated with inflammatory bowel diseases. Journal of Clinical Pathology, 2020, 73, 391-402.	1.0	29
198	An Evaluation of the Use of Serum 7-alpha-hydroxycholestenone as a Diagnostic Test of Bile Acid Malabsorption Causing Watery Diarrhea. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 319-323.	1.8	28

#	Article	IF	CITATIONS
199	Clinical predictors of thiopurine-related adverse events in Crohn's disease. World Journal of Gastroenterology, 2015, 21, 7795.	1.4	28
200	Novel CD8+ T-Cell Subsets Demonstrating Plasticity in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1596-1608.	0.9	28
201	Improving the quality of surveillance colonoscopy in inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2019, 4, 971-983.	3.7	28
202	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut, 2020, 69, gutjnl-2020-321927.	6.1	28
203	Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. Journal of Crohn's and Colitis, 2021, 15, 2022-2030.	0.6	28
204	Double percutaneous endoscopic gastrostomy fixation: an effective treatment for recurrent gastric volvulus. American Journal of Gastroenterology, 1993, 88, 1271-2.	0.2	28
205	Structural response of the hamster Sertoli cell to hypophysectomy: A correlative morphometric and endocrine study. The Anatomical Record, 1992, 234, 513-529.	2.3	27
206	Gut mucosal secretion of interleukin 1beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease. Digestive Diseases and Sciences, 2001, 46, 402-409.	1.1	27
207	The Paddington International Virtual Chromoendoscopy Score in ulcerative colitis exhibits very good inter-rater agreement after computerized module training: a multicenter study across academic and community practice (with video). Gastrointestinal Endoscopy, 2018, 88, 95-106.e2.	0.5	27
208	The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2021, 6, 754-769.	3.7	27
209	Effect of hydrostatic pressure on the magnetic, exchange bias and magnetocaloric properties of Ni 45.5 Co 2 Mn 37.5 Sn 15. Journal of Alloys and Compounds, 2017, 712, 714-719.	2.8	26
210	All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: A population-based, open cohort study. Diabetes and Metabolism, 2017, 43, 211-216.	1.4	26
211	Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts. PLoS ONE, 2019, 14, e0221961.	1.1	26
212	Funding a Smoking Cessation Program for Crohn's Disease: An Economic Evaluation. American Journal of Gastroenterology, 2015, 110, 368-377.	0.2	25
213	Crossover Subsets of CD4+ T Lymphocytes in the Intestinal Lamina Propria ofÂPatients with Crohn's Disease and Ulcerative Colitis. Digestive Diseases and Sciences, 2017, 62, 2357-2368.	1.1	25
214	Histopathological Features of Inflammatory Bowel Disease are Associated With Different CD4+ T Cell Subsets in Colonic Mucosal Lamina Propria. Journal of Crohn's and Colitis, 2018, 12, 1448-1458.	0.6	25
215	MnO2-Vertical graphene nanosheets composite electrodes for energy storage devices. Materials Today: Proceedings, 2016, 3, 1686-1692.	0.9	24
216	ls neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease?. European Journal of Gastroenterology and Hepatology, 2001, 13, 1073-1076.	0.8	23

#	Article	IF	CITATIONS
217	Upper gastrointestinal bleeding due to peptic ulcer disease is not associated with air pollution: a case-crossover study. BMC Gastroenterology, 2015, 15, 131.	0.8	23
218	Point of Care Ultrasound Accurately Distinguishes Inflammatory from Noninflammatory Disease in Patients Presenting with Abdominal Pain and Diarrhea. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-7.	0.8	23
219	Joule Heating and mechanical properties of epoxy/graphene based aerogel composite. Composites Science and Technology, 2022, 218, 109199.	3.8	23
220	Arterial uptake indices of low density lipoproteins after fatty streak formation in Cynomolgus monkeys. Cardiovascular Research, 1987, 21, 14-20.	1.8	22
221	Flipping growth orientation of nanographitic structures by plasma enhanced chemical vapor deposition. RSC Advances, 2015, 5, 91922-91931.	1.7	22
222	Plasma-electric field controlled growth of oriented graphene for energy storage applications. Journal Physics D: Applied Physics, 2018, 51, 145303.	1.3	22
223	Engineering high-defect densities across vertically-aligned graphene nanosheets to induce photocatalytic reactivity. Carbon, 2020, 168, 32-41.	5.4	22
224	<i>Clostridium difficile</i> Infection Worsens the Prognosis of Ulcerative Colitis. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 373-380.	0.8	21
225	Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients. Inflammatory Bowel Diseases, 2021, 27, 647-654.	0.9	21
226	Advances in Novel Diagnostic Endoscopic Imaging Techniques in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 873-880.	0.9	20
227	An organic jelly made fractal logic gate with an infinite truth table. Scientific Reports, 2015, 5, 11265.	1.6	20
228	The NOD2 -Smoking Interaction in Crohn's Disease is likely Specific to the 1007 fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study. EBioMedicine, 2017, 21, 188-196.	2.7	20
229	Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease?. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481986301.	1.4	20
230	Insights into the electrochemical capacitor performance of transition metal–vertical graphene nanosheet hybrid electrodes. Physical Chemistry Chemical Physics, 2019, 21, 25196-25205.	1.3	20
231	Diverse Immune Effects of Bovine Colostrum and Benefits in Human Health and Disease. Nutrients, 2021, 13, 3798.	1.7	20
232	Infliximab in refractory coeliac disease. European Journal of Gastroenterology and Hepatology, 2005, 17, 603-604.	0.8	19
233	Advances in the diagnosis and management of inflammatory bowel disease: Challenges and uncertainties. Saudi Journal of Gastroenterology, 2014, 20, 81.	0.5	19
234	Ulcerative Colitis-Associated Hospitalization Costs: A Population-Based Study. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 357-362.	0.8	19

#	Article	IF	CITATIONS
235	Mucosal Healing - How Deep Is Enough?. Digestive Diseases, 2016, 34, 160-164.	0.8	19
236	768 A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate - Severe Crohn's Disease Patients: Results From IM-UNITI. Gastroenterology, 2016, 150, S157-S158.	0.6	19
237	Literature review: impacts of socioeconomic status on the risk of inflammatory bowel disease and its outcomes. European Journal of Gastroenterology and Hepatology, 2017, 29, 879-884.	0.8	19
238	Magnetostructural transition and large magnetocaloric effect in (Mn0.6Fe0.4)NiSi1â^'Al (xÂ=Â0.06–0.08) alloys. Journal of Magnetism and Magnetic Materials, 2020, 500, 166345.	1.0	19
239	Assessment of Endoscopic Healing by Using Advanced Technologies Reflects Histological Healing in Ulcerative Colitis, Journal of Crohn's and Colitis, 2020, 14, 1282-1289 Giant Room-Temperature Magnetocaloric Effect Across the Magnetostructural Transition in	0.6	19
240	<mml:math <br="" display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML">overflow="scroll"><mml:mo stretchy="false">(<mml:mrow><mml:mi>Mn</mml:mi><mml:mi>Ni</mml:mi><mml:mi>Si<td>> <td>·ow><mml:ms< td=""></mml:ms<></td></td></mml:mi></mml:mrow></mml:mo </mml:math>	> <td>·ow><mml:ms< td=""></mml:ms<></td>	·ow> <mml:ms< td=""></mml:ms<>

#	Article	IF	CITATIONS
253	Realization of 3D epoxy resin/Ti ₃ C ₂ T _x MXene aerogel composites for low-voltage electrothermal heating. 2D Materials, 2021, 8, 025022.	2.0	17
254	Therapeutic value ofalpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab. Expert Opinion on Biological Therapy, 2003, 3, 995-1000.	1.4	16
255	Anti-TNF Therapy in Crohn's Disease. Novartis Foundation Symposium, 2008, 263, 193-210.	1.2	16
256	Microscopic Colitis Evolved Into Inflammatory Bowel Diseases Is Characterized by Increased Th1/Tc1 Cells in Colonic Mucosal Lamina Propria. Digestive Diseases and Sciences, 2017, 62, 2755-2767.	1.1	16
257	Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis—An Exploratory Study to Define Deep Remission. Inflammatory Bowel Diseases, 2021, 27, 1719-1730.	0.9	16
258	Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110599.	1.4	16
259	PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis. United European Gastroenterology Journal, 2022, 10, 147-159.	1.6	16
260	Intestinal Entry of Prions. Zeitschrift Fur Gastroenterologie, 2002, 40, 37-40.	0.2	15
261	The Positioning of Colectomy in the Treatment of Ulcerative Colitis in the Era of Biologic Therapy. Inflammatory Bowel Diseases, 2013, 19, 2695-2703.	0.9	15
262	Nano Molecularâ€Platform: A Protocol to Write Energy Transmission Program Inside a Molecule for Bioâ€Inspired Supramolecular Engineering. Advanced Functional Materials, 2014, 24, 1364-1371.	7.8	15
263	The Association of Smoking and Surgery in Inflammatory Bowel Disease is Modified by Age at Diagnosis. Clinical and Translational Gastroenterology, 2016, 7, e165.	1.3	15
264	In-vivo & in-vitro toxicity test of molecularly engineered PCMS: A potential drug for wireless remote controlled treatment. Toxicology Reports, 2018, 5, 1044-1052.	1.6	15
265	Resonant Oscillation Language of a Futuristic Nano-Machine-Module: Eliminating Cancer Cells & Alzheimer Aβ Plaques. Current Topics in Medicinal Chemistry, 2015, 15, 534-541.	1.0	15
266	Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2016, 22, 2711-2723.	0.9	14
267	What do changes in inflammatory bowel disease management mean for our patients?. Journal of Crohn's and Colitis, 2012, 6, S243-S249.	0.6	13
268	Domino ring-opening–ring-closing enyne metathesis vs enyne metathesis of norbornene derivatives with alkynyl side chains. Construction of condensed polycarbocycles. Beilstein Journal of Organic Chemistry, 2018, 14, 2708-2714.	1.3	13
269	Diet and Nutrition in IBD—Progress and Gaps. Nutrients, 2019, 11, 1740.	1.7	13
270	Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK. Journal of Crohn's and Colitis, 2020, 14, 1769-1776.	0.6	13

#	Article	IF	CITATIONS
271	Biologic Therapies: Lessons from Multiple Sclerosis. Digestive Diseases, 2012, 30, 383-386.	0.8	12
272	Length of hospital stay is shorter in black and ethnic minority patients with diabetes. Diabetic Medicine, 2012, 29, 830-831.	1.2	12
273	Spectroscopically forbidden infra-red emission in Au-vertical graphene hybrid nanostructures. Nanotechnology, 2017, 28, 465703.	1.3	12
274	Structural studies of spray pyrolysis synthesized oxygen deficient anatase TiO ₂ thin films by using X-ray absorption spectroscopy. Physical Chemistry Chemical Physics, 2019, 21, 6198-6206.	1.3	12
275	A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients With Ulcerative Colitis, Using the Pictorial Representation of Illness and Self-measure Tool. Journal of Crohn's and Colitis, 2021, 15, 228-237.	0.6	12
276	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. Autoimmunity Reviews, 2021, 20, 102849.	2.5	12
277	Gut Microbiota, Macrophages and Diet: An Intriguing New Triangle in Intestinal Fibrosis. Microorganisms, 2022, 10, 490.	1.6	12
278	Primary chronic intestinal pseudo-obstruction—an update. Postgraduate Medical Journal, 1994, 70, 65-67.	0.9	11
279	Achalasia of the Oesophagus in Elderly Patients responds Poorly to Conservative Therapy. Age and Ageing, 1994, 23, 280-282.	0.7	11
280	Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease. Inflammatory Bowel Diseases, 2017, 23, E26-E37.	0.9	11
281	Reversible magnetocaloric effect and critical exponent analysis in Mn-Fe-Ni-Sn Heusler alloys. Journal of Alloys and Compounds, 2018, 746, 200-205.	2.8	11
282	Randomized controlled study of the prediction of diminutive/small colorectal polyp histology using didactic versus computerâ€based selfâ€learning module in gastroenterology trainees. Digestive Endoscopy, 2019, 31, 535-543.	1.3	11
283	Dietary patterns, food groups and nutrients in Crohn's disease: associations with gut and systemic inflammation. Scientific Reports, 2021, 11, 1674.	1.6	11
284	Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls. Intestinal Research, 2017, 15, 160.	1.0	11
285	New tools and approaches for improved management of inflammatory bowel diseases. Journal of Crohn's and Colitis, 2014, 8, 1246-1253.	0.6	10
286	The Rising Burden of Inflammatory Bowel Disease in North America from 2015 to 2025: A Predictive Model. American Journal of Gastroenterology, 2015, 110, S829.	0.2	10
287	A simultaneous one pot synthesis of two fractal structures via swapping two fractal reaction kinetic states. Physical Chemistry Chemical Physics, 2016, 18, 14772-14775.	1.3	10
288	Influence of nitrogen on the growth of vertical graphene nanosheets under plasma. Journal of Materials Science, 2018, 53, 7316-7325.	1.7	10

#	Article	IF	CITATIONS
289	The Risk of Inflammatory Bowel Disease in Subjects Presenting With Perianal Abscess: Findings From the THIN Database. Journal of Crohn's and Colitis, 2019, 13, 600-606.	0.6	10
290	Utility of HbA _{1c} assessment in people with diabetes awaiting liver transplantation. Diabetic Medicine, 2019, 36, 1444-1452.	1.2	10
291	A multicentre development and validation study of a novel lower gastrointestinal bleeding score—The Birmingham Score. International Journal of Colorectal Disease, 2020, 35, 285-293.	1.0	10
292	Electrochemical properties of vertically aligned graphenes: tailoring heterogeneous electron transfer through manipulation of the carbon microstructure. Nanoscale Advances, 2020, 2, 5319-5328.	2.2	10
293	Acute gastric dilatationa delayed complication of percutaneous endoscopic gastrostomy Gut, 1993, 34, 859-860.	6.1	9
294	Learning the Lessons of Antitumour Necrosis Factor Therapy-Associated Psoriasis. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 674-676.	1.8	9
295	Dynamic Position Change at Colonoscopy Improves Adenoma Detection. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 508-508.	1.8	9
296	Predictors of Mortality among Patients Undergoing Colectomy for Ischemic Colitis: A Population-Based, United States Study. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 600-604.	0.8	9
297	Tofacitinib in ulcerative colitis. Immunotherapy, 2016, 8, 495-502.	1.0	9
298	Ustekinumab: a novel therapeutic option in Crohn's disease. Expert Opinion on Biological Therapy, 2016, 16, 1065-1074.	1.4	9
299	Total Synthesis of the Marine Polyketide (â^')-Gracilioether F. Journal of Organic Chemistry, 2017, 82, 7675-7682.	1.7	9
300	Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. Inflammatory Bowel Diseases, 2020, 26, 961-969.	0.9	9
301	Defining difficult-to-treat inflammatory bowel disease: why and how. The Lancet Gastroenterology and Hepatology, 2021, 6, 520-522.	3.7	9
302	Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19. Frontiers in Medicine, 2020, 7, 613475.	1.2	9
303	Effect of Annealing on the Structural Properties of Vertical Graphene Nanosheets. Advanced Science, Engineering and Medicine, 2016, 8, 146-149.	0.3	9
304	Smoking Is Associated with an Increased Risk for Surgery in Diverticulitis: A Case Control Study. PLoS ONE, 2016, 11, e0153871.	1.1	9
305	Observation of giant exchange bias effect in Ni–Mn–Ti all-d-metal Heusler alloy. Journal of Physics Condensed Matter, 2022, 34, 105801.	0.7	9
306	OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme. Journal of Crohn's and Colitis, 2022, 16, i036-i037.	0.6	9

#	Article	IF	CITATIONS
307	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clinical Gastroenterology and Hepatology, 2022, 20, 2619-2627.e1.	2.4	9
308	Intestinal strictures in Crohn's disease: a 2021 update. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211049.	1.4	9
309	Routine Duodenal Biopsies to Diagnose Celiac Disease. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 385-385.	1.8	8
310	Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Inflammatory Bowel Diseases, 2014, 20, 2046-2055.	0.9	8
311	High definition i-SCAN endoscopy with water immersion technique accurately reflects histological severity of celiac disease. Endoscopy International Open, 2016, 04, E540-E546.	0.9	8
312	Evolving Trends in the Epidemiology of IBD in the 21st Century: A Systematic Review of Population-Based Studies. American Journal of Gastroenterology, 2017, 112, S319-S320.	0.2	8
313	Can a transition clinic bridge the gap between paediatric and adult inflammatory bowel disease care models?. Digestive and Liver Disease, 2020, 52, 516-527.	0.4	8
314	Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease. PLoS ONE, 2021, 16, e0252210.	1.1	8
315	Measurement protocols dependent giant magnetocaloric effect in MnNiSi-based system. Applied Physics Letters, 2021, 119, .	1.5	8
316	Diet–Microbiota Interplay: An Emerging Player in Macrophage Plasticity and Intestinal Health. International Journal of Molecular Sciences, 2022, 23, 3901.	1.8	8
317	Reproducibility of the electronic chromoendoscopy PICaSSO score (Paddington International Virtual) Tj ETQq1 : multicenter international study (with video). Gastrointestinal Endoscopy, 2022, 96, 73-83.	l 0.784314 0.5	rgBT /Overlo 8
318	The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211023.	1.4	8
319	Gut luminal neutrophil migration is influenced by the anatomical site of Crohn's disease. European Journal of Gastroenterology and Hepatology, 2001, 13, 239-243.	0.8	7
320	Efficient control of pandemic 2009 H1N1 virus infection with intravenous zanamivir despite the lack of immune function. Transplant Infectious Disease, 2012, 14, 657-659.	0.7	7
321	Topical Therapy in Ulcerative Colitis: Always a Bridesmaid but Never a Bride?. Gastroenterology, 2015, 148, 701-704.	0.6	7
322	445 The TOUCHSTONE Study: A Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis. Gastroenterology, 2015, 148, S-93.	0.6	7
323	A novel method to identify fat malabsorption: The Serum Retinyl Palmitate Test. Clinica Chimica Acta, 2015, 438, 103-106.	0.5	7
324	Newly recognized non-adenomatous lesions associated with enteric carcinomas in inflammatory bowel disease – Report of six rare and unique cases. Annals of Diagnostic Pathology, 2020, 44, 151455.	0.6	7

#	Article	IF	CITATIONS
325	Dysregulation of IL6/IL6R-STAT3-SOCS3 signaling pathway in IBD-associated colorectal dysplastic lesions as compared to sporadic colorectal adenomas in non-IBD patients. Pathology Research and Practice, 2020, 216, 153211.	1.0	7
326	Revisiting the distinct histomorphologic features of inflammatory bowel disease–associated neoplastic precursor lesions in the SCENIC and post–DALM Era. Human Pathology, 2020, 100, 24-37.	1.1	7
327	Physical Activity in Patients With Inflammatory Bowel Disease: A Narrative Review. Inflammatory Bowel Diseases, 2022, 28, 1100-1111.	0.9	7
328	Constrained multiple instance learning for ulcerative colitis prediction using histological images. Computer Methods and Programs in Biomedicine, 2022, 224, 107012.	2.6	7
329	Percutaneous endoscopic gastrostomy–a user's perspective. Journal of Human Nutrition and Dietetics, 1994, 7, 231-235.	1.3	6
330	Management of the Pregnant Inflammatory Bowel Disease Patient on Antitumour Necrosis Factor Therapy: State of the Art and Future Directions. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 505-509.	0.8	6
331	327 A Randomized Comparison of High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy Using iSCAN for Detection of Colonic Dysplastic Lesions During IBD Surveillance Colonoscopy. Gastroenterology, 2015, 148, S-73-S-74.	0.6	6
332	Letter: hydroxypropyl cellulose as therapy for chronic diarrhoea in patients with bile acid malabsorption – possible mechanisms. Alimentary Pharmacology and Therapeutics, 2016, 44, 306-307.	1.9	6
333	513 Pregnancy Alters the Pharmacokinetics of Infliximab and Adalimumab in IBD Women. Gastroenterology, 2016, 150, S105.	0.6	6
334	P283 Bowel urgency in patients with moderate to severe ulcerative colitis: prevalence and correlation with clinical outcomes, biomarker levels, and health-related quality of life from U-ACHIEVE, a Phase 2b study of upadacitinib. Journal of Crohn's and Colitis, 2019, 13, S240-S241.	0.6	6
335	Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. The Lancet Gastroenterology and Hepatology, 2022, 7, 390-391.	3.7	6
336	Advanced technology for assessment of endoscopic and histological activity in ulcerative colitis: a systematic review and meta-analysis. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210925.	1.4	6
337	Â4 Integrin blockade in inflammatory bowel disease. Annals of the Rheumatic Diseases, 2003, 62, 70ii-72.	0.5	5
338	Extracorporeal photopheresis for the treatment of Crohn's disease. Transfusion and Apheresis Science, 2015, 52, 183-186.	0.5	5
339	445 The TOUCHSTONE Study: a Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis. Gastrointestinal Endoscopy, 2015, 81, AB147.	0.5	5
340	Persistent Enhancement on Contrast-Enhanced Ultrasound Studies of Severe Crohn's Disease: Stuck Bubbles?. Ultrasound in Medicine and Biology, 2018, 44, 2189-2198.	0.7	5
341	Healthcare Providers Underestimate Patients' Glucocorticoid Use in Crohn's Disease. Digestive Diseases and Sciences, 2019, 64, 1142-1149.	1.1	5
342	Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas. Frontiers in Medicine, 2020, 7, 576891.	1.2	5

#	Article	IF	CITATIONS
343	Identifying Efficient Cooling Approach of Cylindrical Lithiumâ€lon Batteries. Energy Technology, 2022, 10, 2100888.	1.8	5
344	OP15 A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, i015-i017.	0.6	5
345	Evaluation of the mechanisms of sarcopenia in chronic inflammatory disease: protocol for a prospective cohort study. Skeletal Muscle, 2021, 11, 27.	1.9	5
346	Cephradine-Associated Immune Neutropenia. New England Journal of Medicine, 1985, 312, 651-651.	13.9	4
347	Evaluation of surgeons' marking of excision margins for superficial facial skin cancer lesions. Journal of Laryngology and Otology, 2009, 123, 195-198.	0.4	4
348	Unprecedented C-Methylation at the 2-Position of 2-Carboxy-4-Chromanones – A Case Study with the Corey–Chaykovsky Reagent. Synlett, 2014, 25, 2649-2653.	1.0	4
349	Novel concepts in inflammatory bowel disease. British Medical Bulletin, 2014, 109, 55-72.	2.7	4
350	Novel irregular vascular pattern features of serrated adenoma detected by high-definition iScan endoscopic technique. Gastrointestinal Endoscopy, 2014, 79, 182-184.	0.5	4
351	Targeting Integrins and Safety in an Emerging Class of TargetedÂOral Therapies: Are We Prepared for Rational andÂPrecision Choices?. Gastroenterology, 2015, 149, 1669-1672.	0.6	4
352	Sa1754 Distinctive Th17 Lymphocyte Plasticity in Intestinal Lamina Propria of IBD Patients Compared With Healthy Controls. Gastroenterology, 2015, 148, S-323.	0.6	4
353	Is an Ounce of Prevention Worth a Pound of Cure: Postoperative Recurrence of Crohn's Disease?. Gastroenterology, 2016, 150, 1521-1524.	0.6	4
354	Safety and Efficacy of Long-term Treatment With Ozanimod: An Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis - TOUCHSTONE Extension 2-Year Follow-up. American Journal of Gastroenterology, 2017, 112, S321.	0.2	4
355	P359 Correlation between physician and patient disease assessments in ulcerative colitis: baseline data from the ICONIC study of 1816 patients in 33 countries. Journal of Crohn's and Colitis, 2017, 11, S259-S260.	0.6	4
356	P680 Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn's disease: results from IM-UNITI long-term extension through 2 years. Journal of Crohn's and Colitis, 2019, 13, S459-S460.	0.6	4
357	Chronic inflammation and other changes are significant components of clinically fibrotic strictures in Crohn's disease: a histological study of resected strictures clinically characterized as noninflamed. European Journal of Gastroenterology and Hepatology, 2020, 32, 1432-1439.	0.8	4
358	Radio Waveguide–Double Ratchet Rotors Work in Unison on a Surface to Convert Heat into Power. Nano Letters, 2020, 20, 6891-6898.	4.5	4
359	The introduction of the IBD Disk in Poland – a new tool for assessing disability in patients with inflammatory bowel disease. Przeglad Gastroenterologiczny, 2020, 15, 55-59.	0.3	4
360	OP26 The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in ulcerative colitis. Journal of Crohn's and Colitis, 2020, 14, S023-S024.	0.6	4

#	Article	IF	CITATIONS
361	Training methods in optical diagnosis and characterization of colorectal polyps: a systematic review and meta-analysis. Endoscopy International Open, 2021, 09, E716-E726.	0.9	4
362	Implications of COVID-19 for patients with pre-existing digestive diseases: an update. The Lancet Gastroenterology and Hepatology, 2021, 6, 258-260.	3.7	4
363	Unused to useful: Recycling plasma chamber coated waste composite of ZnO and α-Fe2O3 into an active material for sustainable waste-water treatment. Chemical Engineering Journal Advances, 2021, 7, 100120.	2.4	4
364	The use of 5-aminosalicylates in Crohn's disease: a retrospective study using the UK Clinical Practice Research Datalink. Annals of Gastroenterology, 2020, 33, 500-507.	0.4	4
365	The challenges of medication non-adherence in ulcerative colitis: Practical suggestions to help patients. Journal of Crohn's and Colitis, 2008, 2, 97-98.	0.6	3
366	Subsequent Entry Biologics – Opportunities and Challenges. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 565-565.	1.8	3
367	Role of Immunosuppressives in Special Situations: Perianal Disease and Postoperative Period. Digestive Diseases, 2014, 32, 92-95.	0.8	3
368	812f Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals With Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S1268.	0.6	3
369	The Crohn's Disease–Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clinical Gastroenterology and Hepatology, 2016, 14, e121-e122.	2.4	3
370	P317 Characterisation of patients with delayed response to ustekinumab for Crohn's disease. Journal of Crohn's and Colitis, 2019, 13, S259-S260.	0.6	3
371	P296 Effect of upadacitinib on patient-reported symptoms by the new Ulcerative Colitis Symptoms Questionnaire (UC-SQ) in patients with moderate to severe ulcerative colitis: data from the Phase 2b study U-ACHIEVE. Journal of Crohn's and Colitis, 2019, 13, S247-S248.	0.6	3
372	Performance measures in inflammatory bowel disease surveillance colonoscopy: Implementing changes to practice improves performance. Digestive Endoscopy, 2020, 32, 592-599.	1.3	3
373	Tests that now deserve to be more widely adopted in IBD clinical practice. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094408.	1.4	3
374	Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease. Advances in Therapy, 2021, 38, 2339-2352.	1.3	3
375	131 SAFETY OF USTEKINUMAB IN IBD: A COMPREHENSIVE ANALYSIS OF MAJOR CARDIOVASCULAR EVENTS (MACE) THROUGH 5 YEARS IN CD AND 2 YEARS IN UC. Gastroenterology, 2021, 160, S-37.	0.6	3
376	Association between Week Eight Mayo Subscores and Hospitalization Rates in Adalimumab-treated Patients with Ulcerative Colitis from ULTRA 1 and ULTRA 2. American Journal of Gastroenterology, 2013, 108, S506.	0.2	3
377	Tofacitinib Has Induction Efficacy in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior TNF Inhibitor Therapy. American Journal of Gastroenterology, 2016, 111, S261.	0.2	3
378	Space and Time Crystal Engineering in Developing Futuristic Chemical Technology. ChemEngineering, 2021, 5, 67.	1.0	3

#	Article	IF	CITATIONS
379	Maintenance therapy versus episodic therapy with infliximab for Crohn's disease. Nature Reviews Gastroenterology & Hepatology, 2004, 1, 80-81.	1.7	2
380	Tu1272 Cumulative Incidence of First Intestinal Surgery in Adult and Pediatric Crohn's Disease: A Systematic Review and Meta-Analysis. Gastroenterology, 2012, 142, S-790.	0.6	2
381	Are Patient-Reported Outcome Measures the Way to go in Inflammatory Bowel Disease?. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 535-535.	0.8	2
382	Intestinal Microparticles and Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2014, 20, 771-775.	0.9	2
383	857 Ozanimod Induces Histological Response and Remission: Results From the TOUCHSTONE Study, a Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis. Gastroenterology, 2016, 150, S183.	0.6	2
384	Post-operative Recurrence of Crohn's Disease: There Is More to It than Meets the Eye. Journal of Crohn's and Colitis, 2016, 10, 999-1000.	0.6	2
385	Long-Term Efficacy and Safety of Ustekinumab for Crohn's Disease: Results From Im-Uniti Long-Term Extension Through two Years. Gastroenterology, 2017, 152, S585.	0.6	2
386	High-definition-iSCAN virtual chromoendoscopy has high sensitivity and specificity for the diagnosis of eosinophilic esophagitis. Endoscopy International Open, 2017, 05, E613-E621.	0.9	2
387	Effect of Maintenance Ustekinumab on Corticosteroid-Free Clinical Outcomes in Patients with Crohn's Disease. Gastroenterology, 2017, 152, S595.	0.6	2
388	OC-043â€Long term efficacy and safety of ustekinumab for crohn's disease: results from im-uniti long-term extension through 2 years. , 2017, , .		2
389	OP014 Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension. Journal of Crohn's and Colitis, 2017, 11, S9-S9.	0.6	2
390	Temporal and external validation of a prediction model for adverse outcomes among inpatients with diabetes. Diabetic Medicine, 2018, 35, 798-806.	1.2	2
391	Effect of Si Doping on Magnetic and Magnetocaloric Properties of Ni–Co–Mn–Sn Alloys. IEEE Transactions on Magnetics, 2018, 54, 1-5.	1.2	2
392	P096 The anti-inflammatory effects of niclosamide on cytokines produced by PBMCs derived from IBD patients. Journal of Crohn's and Colitis, 2019, 13, S134-S134.	0.6	2
393	P410 Extraintestinal manifestations and quality of life in patients with ulcerative colitis: 1-year data from ICONIC. Journal of Crohn's and Colitis, 2019, 13, S314-S315.	0.6	2
394	P105 THE PROGRESSION OF INFLAMMATORY BOWEL DISEASE THROUGHOUT LATIN AMERICA: A SYSTEMATIC REVIEW. Inflammatory Bowel Diseases, 2019, 25, S51-S51.	0.9	2
395	Emerging Vertical Nanostructures for High-Performance Supercapacitor Applications. Environmental Chemistry for A Sustainable World, 2019, , 163-187.	0.3	2
396	P254 Re-defining the concept of endoscopic and histological healing by using electronic virtual chromoendoscopy and probe confocal endomicroscopy in ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S223-S224.	0.6	2

#	Article	IF	CITATIONS
397	P148 Reproducibility of PICaSSO score by using narrow banding images (NBI) to assess mucosal and histological healing in ulcerative colitis (UC) patients. Journal of Crohn's and Colitis, 2020, 14, S211-S212.	0.6	2
398	Magnetic and magnetocaloric properties in double perovskite multiferroic Y2NiMnO6 nanoparticle. AIP Conference Proceedings, 2020, , .	0.3	2
399	Sequential ring-closing enyne metathesis and intramolecular Diels–Alder reaction: an approach to the synthesis of the core structure of galiellalactone. Journal of Chemical Sciences, 2020, 132, 1.	0.7	2
400	Speedy one-pot electrochemical synthesis of giant octahedrons from in situ generated pyrrolidinyl PAMAM dendrimer. Soft Matter, 2020, 16, 9140-9146.	1.2	2
401	A Multicenter Study of Patient Acceptability of the IBD Disk Tool and Patient-Reported Disabilities. Digestive Diseases and Sciences, 2022, 67, 457-462.	1.1	2
402	P397 Response to biologics in IBD patients assessed by Computerized image analysis of Probe Based Confocal Laser Endomicroscopy with molecular labeling. Journal of Crohn's and Colitis, 2021, 15, S406-S407.	0.6	2
403	Diet in Intestinal Fibrosis: A Double-Edged Sword. Nutrients, 2021, 13, 3148.	1.7	2
404	Proteinase 3 (PR3) Autoantibodies as a Serological Marker in Inflammatory Bowel Disease (IBD). American Journal of Gastroenterology, 2013, 108, S523.	0.2	2
405	Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives?—Author's reply. United European Gastroenterology Journal, 2022, 10, 344-345.	1.6	2
406	Management of Crohn's disease from efficacy, quality of life and health economic perspectives. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 587-598.	0.7	1
407	Tu1306 Surgical Rates Have Decreased for Emergent Crohn's Disease Resections While Increasing for Elective Resections: A Population-Based Time Trend Study. Gastroenterology, 2012, 142, S-798.	0.6	1
408	Mo1297 Mode of Delivery in Inflammatory Bowel Disease Patients: A Population-Based Study. Gastroenterology, 2013, 144, S-629.	0.6	1
409	Does vitamin D supplementation impact plasma cathelicidin, human beta defensin 2 and intestinal permeability in stable Crohn's disease? – Results from a randomised, double blind placebo controlled study. Proceedings of the Nutrition Society, 2013, 72, .	0.4	1
410	Clinical Quality Indicators in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 241-241.	0.8	1
411	Ulcerative Colitis – What Can We Learn from the Asia-Pacific Region?. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 122-122.	0.8	1
412	Should We Establish Standards of Care for Management of Elderly Patients with Inflammatory Bowel Disease?. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 236-236.	0.8	1
413	Inflammatory Bowel Disease: Appreciating Disability and Impact of Disease. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 66-66.	0.8	1
414	Exaggerated IL-15 and Altered Expression of foxp3+ Cell-Derived Cytokines Contribute to Enhanced Colitis in Nlrp3â^'/â^' Mice. Mediators of Inflammation, 2016, 2016, 1-12.	1.4	1

#	Article	IF	CITATIONS
415	Mo1832 Validation of Administrative Data for Capturing Crohn's Disease Patients Requiring Surgical Bowel Resection. Gastroenterology, 2016, 150, S788.	0.6	1
416	76 Surgical Resection Rates for Crohn's Disease Are Decreasing: A Population-Based Time Trend Analysis. Gastroenterology, 2016, 150, S20.	0.6	1
417	Ustekinumab is Effective for Inducing Clinical, Endoscopic, and Radiographic Response and Remission in Refractory Moderate-to-Severe Crohn's Disease: A Multicentre Cohort Study. Gastroenterology, 2017, 152, S410-S411.	0.6	1
418	Influence of alkene substituent in dictating the reaction course to form carbocycles or oxacycles during ring closing metathesis of acyclic trienes. Journal of Chemical Sciences, 2017, 129, 1873-1881.	0.7	1
419	Exposure-Response to SC Ustekinumab In Moderate-Severe Crohn's Disease: Results From the IM-UNITI Maintenance Study. American Journal of Gastroenterology, 2017, 112, S365.	0.2	1
420	P258 Abdominal pain and its relationship with clinical outcomes, biomarker levels, and health-related quality of life in patients with moderate to severe ulcerative colitis: data from U-ACHIEVE, a Phase 2b study of upadacitinib. Journal of Crohn's and Colitis, 2019, 13, S226-S226.	0.6	1
421	P322 Disease-related worries and concerns in patients with ulcerative colitis: 1-year data from ICONIC. Journal of Crohn's and Colitis, 2019, 13, S262-S262.	0.6	1
422	899 A MULTICENTRE VALIDATION STUDY OF A NOVEL LOWER GASTROINTESTINAL BLEEDING (LGIB) SCORE-THE BIRMINGHAM (BHAM) SCORE. Gastrointestinal Endoscopy, 2019, 89, AB120-AB121.	0.5	1
423	FRI-061-Colorectal cancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: A systematic review and meta-analysis. Journal of Hepatology, 2019, 70, e412.	1.8	1
424	P343 Efficacy of ustekinumab in Crohn's disease at maintenance Week 56: IM-UNITI study. Journal of Crohn's and Colitis, 2019, 13, S274-S274.	0.6	1
425	P105 THE PROGRESSION OF INFLAMMATORY BOWEL DISEASE THROUGHOUT LATIN AMERICA: A SYSTEMATIC REVIEW. Gastroenterology, 2019, 156, S72-S73.	0.6	1
426	Emotional state should not be used to differentiate IBD from IBS – Authors' reply. The Lancet Gastroenterology and Hepatology, 2020, 5, 723-724.	3.7	1
427	46 THE FIRST REAL-LIFE MULTICENTRE, INTERNATIONAL, PROSPECTIVE VALIDATION STUDY OF THE ELECTRONIC CHROMOENDOSCOPY SCORING SYSTEM (PICASSO-THE PADDINGTON INTERNATIONAL VIRTUAL) T	j ETQq1 1	0,784314 rg
428	Measuring Patient Experience in Inflammatory Bowel Disease Care: A Key Component of Continuous Quality Improvement. Journal of Crohn's and Colitis, 2021, 15, 347-348.	0.6	1
429	DOP88 Effect of risankizumab on patient-reported outcomes in patients with Crohn's Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trials. Journal of Crohn's and Colitis, 2021, 15, S119-S121.	0.6	1
430	Intestinal ultrasonography: a useful skill for efficient, non-invasive monitoring of patients with IBD using a clinic-based point-of-care approach. Frontline Gastroenterology, 2022, 13, 447-451.	0.9	1
431	Absence of detectable measles virus genome sequence in inflammatory bowel disease tissues and peripheral blood lymphocytes. , 1998, 55, 243.		1
432	Indications for Elective Caesarean Section in IBD: A Population-based Study. American Journal of Gastroenterology, 2013, 108, S524-S525.	0.2	1

#	Article	IF	CITATIONS
433	Ustekinumab Is Effective for the Induction and Maintenance of Response in Crohn's Disease: A Multi-center Cohort Study. American Journal of Gastroenterology, 2016, 111, S294.	0.2	1
434	Medical Management of Toxic Megacolon. , 2014, , 359-365.		1
435	A Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study. American Journal of Gastroenterology, 2015, 110, S783.	0.2	1
436	Age at Diagnosis of Crohn's Disease May Explain NOD2-Smoking Interactions. American Journal of Gastroenterology, 2015, 110, S837.	0.2	1
437	Clinical outcomes, predictors of prognosis and health economics consequences in IBD patients after discontinuation of the first biological therapy. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482098121.	1.4	1
438	OP16 The first virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic remission in Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, i017-i018.	0.6	1
439	The Importance of Physical Activity in Patients With Inflammatory Bowel Disease: A Narrative Review. Inflammatory Bowel Diseases, 2021, , .	0.9	1
440	Disease activity, burden and suffering in patients with ulcerative colitis in the UK cohort recruited into the global ICONIC study. Frontline Gastroenterology, 2023, 14, 25-31.	0.9	1
441	Platelets in chronic granulocytic leukemia. Plasma Therapy and Transfusion Technology, 1987, 8, 67-68.	0.2	Ο
442	Reduced long-term survival following major peptic ulcer haemorrhage. British Journal of Surgery, 1997, 84, 265-268.	0.1	0
443	How effective is adalimumab for inducing remission in patients with moderate-to-severe Crohn's disease?. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 540-541.	1.7	0
444	Prevalence and QoL impact of biologics on CD and UC: Results from the EFCCA patient survey. Inflammatory Bowel Diseases, 2007, 13, 662.	0.9	0
445	Assessment of the early regenerative therapeutic response in graft versus host disease using high definition technology with virtual i-Scan chromoendoscopy. Endoscopy, 2013, 45, E389-E390.	1.0	Ο
446	Cumulative Incidence of Second Major Abdominal Surgery Crohn's Disease: A Systematic Review and Meta-analysis of Population-based Studies. American Journal of Gastroenterology, 2013, 108, S525-S526.	0.2	0
447	Unprecedented C-Methylation at the 2-Position of 2-Carboxy-4-Chromanones – A Case Study with the Corey–Chaykovsky Reagent. Synlett, 2014, 25, e4-e4.	1.0	Ο
448	Letter: dermatological complications with therapy for inflammatory bowel disease – authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 39, 233-234.	1.9	0
449	Reply to Does Cigarette Smoke Extract Really Bring Out Different Effects on Dendritic Cells from Ulcerative Colitis and Crohn's Disease?. Inflammatory Bowel Diseases, 2014, 20, E26-E27.	0.9	Ο
450	Reply to Mendall. Inflammatory Bowel Diseases, 2014, 20, e13.	0.9	0

#	Article	IF	CITATIONS
451	Unprecedented C-Methylation at the 2-Position of 2-Carboxy- 4-Chromanones – A Case Study with the Corey–Chaykovsky Reagent. Synlett, 2015, 26, 2472-2472.	1.0	0
452	Reply to Villanacci et al Endoscopy, 2015, 47, 760-760.	1.0	0
453	Sa1861 Ileal and Colonic Foxp3+ IFNg+ T Cell Prevalence Provides Evidence of Treg-Th1 Plasticity in Humans. Gastroenterology, 2016, 150, S384.	0.6	0
454	1076 A Simple, Validated Ultrasonographic Score for the Detection of Inflammation in Established Crohn's Disease. Gastroenterology, 2016, 150, S213.	0.6	0
455	Sa1969 Gene Expression of Matrix Metalloproteinase-3 in Lamina Propria Mononuclear Cells Predicts Response to TNF Inhibitors in Colonic Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S419-S420.	0.6	0
456	1074 The Concordance Between Disease Activity and Prevalence of Th1 Subsets in Patients With Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S212-S213.	0.6	0
457	Mo1743 Accuracy and Inter-Observer Agreement for Characterization of Colonic Polyps Using the New Optical Enhancement -iSCAN Closefocusâ,,¢ Colonoscope. Gastroenterology, 2016, 150, S769.	0.6	0
458	Mo2093 Histological Chronicity and Subtle Mucosal and Vascular Architectural Changes Can Be Assessed by Novel Endoscopic Techniques in Patients With Ulcerative Colitis. Gastroenterology, 2016, 150, S830.	0.6	0
459	Sa2028 Inter-Observer Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease. Gastroenterology, 2016, 150, S433-S434.	0.6	0
460	Su2069 Early Detection and Endomicroscopic Assessment of GvHD in the GI Tract by Confocal Laser Endomicroscopy. Gastroenterology, 2016, 150, S626.	0.6	0
461	P-106 Examination of an Alternative Definition for Clinical Remission in UC. Inflammatory Bowel Diseases, 2016, 22, S43.	0.9	0
462	Dietary Intake of Patients with Crohn's Disease in Remission: A Single Center Experience. Gastroenterology, 2017, 152, S1015.	0.6	0
463	Development and Reliability of the New Endoscopic Virtual Chromoendoscopy Score: The Picasso Score (The Paddington International Virtual Chromoendoscopy Score) in UC. Gastroenterology, 2017, 152, S642.	0.6	0
464	Correlation between Physician and Patient Disease Assessments in Ulcerative Colitis: Baseline Data from the Iconic Study of 1816 Patients in 33 Countries. Gastroenterology, 2017, 152, S741.	0.6	0
465	Sa1049 The Virtual Electronic Chromoendoscopy (Vec) Score in Ulcerative Colitis Exhibits Very Good Inter-Rater Agreement in Scoring Mucosal and Vascular Changes After Computerised Module Training: A Study Across Academic and Community Practice. Gastrointestinal Endoscopy, 2017, 85, AB169-AB170.	0.5	0
466	Histological Remission is Predictive of Improved Clinical Outcomes in Patients with Ulcerative Colitis: Results from the Touchstone ole. Gastroenterology, 2017, 152, S597-S598.	0.6	0
467	Location and Kudo Pit Pattern Reflect Neoplastic Histology of Lesions Detected at Surveillance Colonoscopy in Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S642.	0.6	0
468	PWE-142â€A 10-year review of abdominal tuberculosis experience in a single multi-ethnic hospital		0

population., 2017,,.

#	Article	IF	CITATIONS
469	PWE-048â€The virtual electronic chromoendoscopy score in ulcerative colitis exhibits very good inter-rater agreement in scoring mucosal and vascular changes after computerised module training: a study across academic and community practice. , 2017, , .		0
470	PTH-024â€The role of probe confocal laser endomicroscopy with image enhanced endoscopy in characterisation and endoscopic resection of dysplastic lesions in inflammatory bowel diseasepatients. , 2017, , .		0
471	PTH-025â€Predicting polyp histology – development and validation of an international simple endoscopic classification of small colorectal polyps using the novel i-scan optical enhancement colonoscope. , 2017, , .		0
472	P335 A prospective multicentre "real-life―international validation study of the PICaSSO endoscopic scoring system against histologic scoring system to define mucosal healing in ulcerative colitis. Journal of Crohn's and Colitis, 2018, 12, S271-S271.	0.6	0
473	PWE-046â€TH17 cells dominate the colonic mucosal immune response in primary sclerosing cholangitis associated colitis. , 2018, , .		0
474	PWE-067â€Healthcare resource utilisation and QOL in patients with UC by disease severity: iconic baseline data. , 2018, , .		0
475	OWE-014â€Whole transcriptome shotgun sequencing reveals significant upregulation of colonic mucosal immune-mediated anti-microbial mechanisms in psc-uc. , 2018, , .		0
476	ADWE-01â€The prediction of diminutive/small polyp histology using didactic vs computer based training in gastroenterology trainees. , 2018, , .		0
477	ADTU-05â€Gut microbial composition in the migrant south-asian IBD population in UK. , 2018, , .		0
478	P569 A national, retrospective, observational study on the use of 5-aminosalicylates (5-ASA) in Crohn's disease (CD). Journal of Crohn's and Colitis, 2019, 13, S398-S399.	0.6	0
479	P281 Endoscopic healing assessed by advanced optical enhancement techniques combined with faecal calprotectin (FCP) can accurately assess histological healing in ulcerative colitis patients. Journal of Crohn's and Colitis, 2019, 13, S238-S239.	0.6	Ο
480	P623 Colorectal cancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: a systematic review and meta-analysis. Journal of Crohn's and Colitis, 2019, 13, S428-S429.	0.6	0
481	Sa1041 PERFORMANCE MEASURES IN IBD SURVEILLANCE COLONOSCOPY- IMPLEMENTING CHANGES TO PRACTICE IMPROVES PERFORMANCE. Gastrointestinal Endoscopy, 2019, 89, AB149.	0.5	Ο
482	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 796-797.	2.4	0
483	P176 Real-world use of the IBD Disk tool for evaluation of patient-reported disability in the outpatient clinic. Journal of Crohn's and Colitis, 2019, 13, S177-S177.	0.6	0
	P164 Mucosal healing (MH) assessed with PICaSSO (Paddington International Virtual) Tj ETQq0 0 0 rgBT /Overlo	ck 10 Tf 5	0 152 Td (Ch
484	histological normalisation using the ECAP (Extent Chronicity Activity Plus) score. Journal of Crohn's and Colitis, 2019, 13, S170-S171.	0.6	0
485	P222 Purely fibrostenotic Crohn's disease without chronic inflammation is uncommon – a histopathologic study of resected intestine. Journal of Crohn's and Colitis, 2019, 13, S206-S207.	0.6	0
486	P739 The progression of inflammatory bowel disease throughout Latin America: a systematic review. Journal of Crohn's and Colitis, 2019, 13, S490-S491.	0.6	0

#	Article	IF	CITATIONS
487	PTH-138â€Colorectal cancer, colectomy and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis. , 2019, , .		0
488	PWE-047â€Improved patient-reported outcomes with upadacitinib over 52 weeks in patients with moderate-to-severe crohn's disease. , 2019, , .		0
489	IDDF2019-ABS-0130â€Global smoking trends in inflammatory bowel disease: a systematic review of inception cohorts. , 2019, , .		О
490	845â€fPatient and Physician Assessment of Disease Burden in Patients With Early UC: 2-Year Data From ICONIC. American Journal of Gastroenterology, 2019, 114, S489-S490.	0.2	0
491	697 Safety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results From Phase 2 and 3 Studies in Crohn's Disease and Ulcerative Colitis. American Journal of Gastroenterology, 2019, 114, S408-S409.	0.2	Ο
492	P220 Predictors of prognosis after discontinuation of first-use biologics in IBD patients with at least 24 months follow-up. Journal of Crohn's and Colitis, 2020, 14, S252-S253.	0.6	0
493	Elevated interferon-gamma levels during pregnancy are associated with adverse maternofetal outcomes in IBD. Gut, 2020, 69, 1895-1897.	6.1	0
494	P158â€Raman Spectroscopy demonstrates biomolecular changes and predicts response to biological therapy in inflammatory bowel disease. , 2021, , .		0
495	P165â€Disease-related worries and concerns in UK patients with ulcerative colitis: 2-year data from ICONIC. , 2021, , .		Ο
496	Response to Biologics in Ibd Patients Assessed by Computerized Image Analysis of Probe Based Confocal Laser Endomicroscopy With Molecular Labeling. Endoscopy, 2021, 53, .	1.0	0
497	DOP14 Ultra-high magnification endocytoscopy and molecular markers for defining endoscopic and histologic remission in Ulcerative Colitis. Journal of Crohn's and Colitis, 2021, 15, S052-S054.	0.6	О
498	P164â€Correlation between physician and patient disease assessments in ulcerative colitis: 2-Year UK data from ICONIC. , 2021, , .		0
499	P157â€Raman Spectroscopy can differentiate mucosal healing from non-healing in inflammatory bowel disease. , 2021, , .		0
500	O4â€Multicentre prospective validation study of the paddington international virtual chromoendoscopy score (PICaSSO) in ulcerative colitis. , 2021, , .		0
501	Induction Treatment with Anti-TNF Decreases C-Reactive Protein Levels among Crohn's Disease Patients: A Systematic Review and Meta-analysis. American Journal of Gastroenterology, 2013, 108, S540.	0.2	0
502	Response Rates in the Control Arms of Randomized Controlled Trials: A Systematic Review and Meta-analysis of Trials on Monoclonal Antibodies in Ulcerative Colitis. American Journal of Gastroenterology, 2013, 108, S558.	0.2	0
503	Colorectal Neoplasia Surveillance in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: An Economic Evaluation. American Journal of Gastroenterology, 2013, 108, S637.	0.2	0
504	A Cost-Utility Analysis of Smoking Cessation Programs for Patients with Crohn's Disease. American Journal of Gastroenterology, 2013, 108, S525.	0.2	0

#	Article	IF	CITATIONS
505	The Comparative Efficacy of Remission Maintenance Therapy in Crohn's Disease: A Bayesian Network Meta-analysis. American Journal of Gastroenterology, 2013, 108, S535-S536.	0.2	0
506	Different Methodologies for Determining Mayo Score in Clinical Studies Can Influence Disease Activity Assessments in Ulcerative Colitis. American Journal of Gastroenterology, 2014, 109, S476.	0.2	0
507	Postoperative Mortality for the Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies: ACG Fellow Award. American Journal of Gastroenterology, 2014, 109, S639.	0.2	0
508	Predictors of Hospitalization in Patients With Moderately to Severely Active Ulcerative Colitis From ULTRA 1 and ULTRA 2. American Journal of Gastroenterology, 2014, 109, S475.	0.2	0
509	C-Reactive Protein and Erythrocyte Sedimentation Rate Do Not Correlate With Disease Activity in Pregnant Women With IBD. American Journal of Gastroenterology, 2014, 109, S516-S517.	0.2	0
510	The Interaction Between NOD2 and Smoking Is Specific to the 1007fs SNP of the NOD2 Gene in Crohn's Disease: A Systematic Review and Meta-analysis. American Journal of Gastroenterology, 2015, 110, S838.	0.2	0
511	Long-Term Safety of Adalimumab in Clinical Trials in Adult Patients With Crohn's Disease or Ulcerative Colitis. American Journal of Gastroenterology, 2015, 110, S789-S790.	0.2	0
512	Safety and Efficacy of Long-Term Treatment with Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Touchstone Extension. American Journal of Gastroenterology, 2016, 111, S262.	0.2	0
513	Safety of Ustekinumab With and Without Concomitant Corticosteroids or Immunosuppressants in Patients With Moderately to Severely Active Crohn's Disease. American Journal of Gastroenterology, 2017, 112, S329-S330.	0.2	0
514	Paradoxical Trends in Hospitalization Rates for the Inflammatory Bowel Diseases Between the Western World and Newly Industrialized Countries: A Study of the Organization for Economic Cooperation and Development (OECD). American Journal of Gastroenterology, 2017, 112, S321-S323.	0.2	0
515	I-SCAN OPTICAL ENHANCEMENT FOR THE IN VIVO PREDICTION OF DIMINUTIVE COLORECTAL POLYP HISTOLOGY: RESULTS FROM A PROSPECTIVE THREE-PHASED MULTICENTRE TRIAL. Endoscopy, 2018, 50, .	1.0	0
516	Magnetic and magnetocaloric properties in TbCo2Si2 alloy. AlP Conference Proceedings, 2020, , .	0.3	0
517	DOP18 Advanced optical diagnosis technology for assessment of endoscopic and histological remission in Ulcerative Colitis: A systematic review and meta-analysis. Journal of Crohn's and Colitis, 2022, 16, i067-i068.	0.6	0
518	P171 PSC/IBD and IBD have similar type and location of colonic lesions, but Dye ChromoEndoscopy (DCE) increases detection rate compared to White Light Endoscopy (WLE). Journal of Crohn's and Colitis, 2022, 16, i241-i242.	0.6	0
519	Crohn's disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial. BMJ Open Gastroenterology, 2022, 9, e000841.	1.1	0
520	Extracorporeal shock wave lithotripsy for bile duct stones using a piezoelectric lithotriptor: the Scottish lithotriptor centre experience. Journal of the Royal College of Surgeons of Edinburgh, 1996, 41, 35-9.	0.1	0
521	Acute Severe Ulcerative Colitis. , 0, , 182-189.		0
522	A VIRTUAL CHROMOENDOSCOPY ARTIFICIAL INTELLIGENCE SYSTEM TO DETECT ENDOSCOPIC AND HISTOLOGIC REMISSION IN ULCERATIVE COLITIS. Endoscopy, 2022, 54, .	1.0	0

#	Article	IF	CITATIONS
523	ADVANCED TECHNOLOGY FOR ASSESSMENT OF ENDOSCOPIC AND HISTOLOGICAL REMISSION IN ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Endoscopy, 2022, 54, .	1.0	0